Ilex Expects Priority Review For Clofarabine; Genzyme Sees Longer Timeframe
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Ilex believes its pediatric leukemia agent clofarabine will receive a priority review from FDA, setting the user fee date at Sept. 29.